Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMBFPO1)

Drug Name
F-8-IL-10 fusion protein Drug Info
Synonyms Dekavil; F-8-IL-10; F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis); F-8-IL-10 fusion protein (rheumatoid arthritis/endometriosis), Philogen
Indication
Disease Entry ICD 11 Status REF
Endometriosis GA10 Phase 2 [1]
Rheumatoid arthritis FA20 Phase 2 [2]
Inflammatory bowel disease DD72 Phase 1 [2]
Cross-matching ID
TTD Drug ID
DMBFPO1

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-10 (IL10) TTT0Q1F IL10_HUMAN Modulator [3]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Interleukin-10 (IL10) DTT IL10 5.87 4.853 5.092 5.629
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

ICD Disease Classification 16 Disease of the genitourinary system
Disease Class ICD-11: GA10 Endometriosis
The Studied Tissue Endometrium tissue
The Studied Disease Endometriosis [ICD-11:GA10]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin-10 (IL10) DTT IL10 1.07E-02 0.08 0.56
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT02270632) A Randomized, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Efficacy of F8IL10 Dekavil) in Patients With Active RA Receiving MTX. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther. 2009;11(5):R142.